Reynoso Jamie L. sold $33K of CLOV

Reynoso Jamie L. (CEO, Medicare Advantage) sold 6,229 shares of CLOVER HEALTH INVESTMENTS, CORP. /DE (CLOV) at $5.26 on 2026-07-06 under a Rule 10b5-1 trading plan.

Original reporting
SEC EDGAR · Reynoso Jamie L.
Published Jul 6, 2026, 9:57 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Jul 6, 2026, 9:59 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AlphAI market briefInsider activity
Primary signal
$CLOV
Neutral
high confidence
Mentioned
$CLOV
Relevance
2/10
AlphAI data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$CLOVNeutralLow
01

Why it matters

The disclosed open-market sale by the CEO may slightly affect sentiment, but the presence of a pre-arranged 10b5-1 plan typically limits interpretability as a new fundamental signal.

02

Market read

Traders may monitor for patterns in insider activity, but this specific disclosure is unlikely to drive a major repricing without accompanying company-specific news.

03

What to watch

The filing does not state whether additional sales/buys occurred around the same period, nor does it provide context on total insider ownership changes beyond the post-transaction share count.

Relevance 2/10Novelty 3/10Timing: Filed same day (2026-07-06) after-hours/late session SEC Form 4 disclosure.

Background

The article is a primary-source SEC Form 4 insider transaction for Clover Health Investments Corp./DE.

Company-level read

Ticker impact

$CLOVNeutralHigh confidence
Context

Clover Health CEO Jamie L. Reynoso sold 6,229 shares on 2026-07-06 at $5.2600/share under a 10b5-1 plan.

Expected impact

Low near-term impact; any reaction is likely muted and short-lived.

Evidence & confidence

This is a Form 4 insider transaction with a stated pre-arranged 10b5-1 plan, and the article provides no new operational/regulatory catalyst.

Market effects

Minimal; insider sale in a single healthcare payer/MA name does not materially change sector fundamentals.

None indicated.

None indicated.

Counterpoint

Because it’s explicitly a 10b5-1 plan, the sale may reflect scheduled liquidity needs rather than negative expectations.

Key entities

  • Clover Health Investments Corp./DE

    Subject of the Form 4 insider transaction disclosure.

  • Reynoso Jamie L.

    CEO, Medicare Advantage; sold shares under a 10b5-1 plan.

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

Related articles

$UNHMed

Medicare, Medicaid Overhaul Targets Fraudulent Billing and Unauthorized Marketplace Enrollments

CMS proposed reforms to combat fraud in Medicare, Medicaid, CHIP, and the Health Insurance Marketplace, aiming to save $90B over 10 years. The rule strengthens oversight, requires self-reporting of overpayments, and increases transparency. Managed care stocks fell, including UNH, HUM, CVS, CLOV, CNC, MOH, ELV, and OSCR. Medicare anti-fraud efforts saved $41.9B in 2025, with a $22.30 return per dollar spent.

$HUMHighAI 9/10

Humana (HUM) Stock Hits New 52-Week High

Humana (HUM) reached a new 52-week high after reporting Q3 2026 earnings with a smaller loss and raised full-year EPS guidance. Competitors like CVS Health and Elevance Health also saw gains. Clover Health (CLOV) reported Q3 2026 earnings with a slight profit and raised full-year targets.

$CLOVHighAI 8/10

Clover Health (CLOV) Q3 2026 Earnings Call Transcript

Clover Health (CLOV) reported Q3 2026 earnings, highlighting 49% YoY membership growth to 157,000 members, 57% revenue increase to $2.3B, and doubled adjusted EBITDA to $97M. The company achieved high Star Ratings for its plans and improved HEDIS quality performance. Clover Assistant's engagement accelerated, driving better care and economics. The board appointed Clay Thornton as permanent CFO. Management expects continued growth and profitability in 2027 and 2028.